Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BnH-015B in Healthy Volunteers and Alzheimer's Disease Patients
NCT06535308Phase 1Recruiting
- Sponsor
- BnH Research
- Start
- Oct 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BnH-015B in Alzheimer's disease (AD) (12 arms), sponsored by BnH Research. Primary endpoints: Number of occurrences, affected participants with adverse events and Pharmacokinetic (PK) plasma concentration of BnH-015B at 48 hours. Started Oct 2024; status: recruiting.
02
Drugs
BnH-015B
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06535308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06535308.